EDUARDO MARTINHO JUNIOR
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
LIM/23 - Laboratório de Psicopatologia e Terapêutica Psiquiátrica, Hospital das Clínicas, Faculdade de Medicina
LIM/23 - Laboratório de Psicopatologia e Terapêutica Psiquiátrica, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
bookPart Transtornos de personalidade(2019) BRAñAS, Marcelo José Abduch Adas; CROCI, Marcos Signoretti; MARTINHO JUNIOR, Eduardo- Neuroimaging Studies of Nonsuicidal Self-Injury in Youth: A Systematic Review(2021) BRANAS, Marcelo J. A. A.; CROCI, Marcos S.; SALTO, Ana Beatriz Ravagnani; DORETTO, Victoria F.; MARTINHO, Eduardo; MACEDO, Marcos; MIGUEL, Euripedes C.; ROEVER, Leonardo; PAN, Pedro M.Nonsuicidal self-injury (NSSI) is prevalent and affects mainly the youth population. It is prospectively associated with suicide attempts, making it a target for suicide prevention. Recently, several studies have investigated neural pathways of NSSI using neuroimaging. However, there is a lack of systematized appraisal of these findings. This systematic review aims to identify and summarize the main neuroimaging findings of NSSI in youth. We followed PRISMA statement guidelines and searched MEDLINE, APA PsycInfo, and Google Scholar databases for neuroimaging studies, irrespective of imaging modality, specifically investigating NSSI in samples with a mean age of up to 25 years old. Quality assessment was made using the Newcastle-Ottawa and Joanna Briggs Institute scales. The initial search retrieved 3030 articles; 21 met inclusion criteria, with a total of 938 subjects. Eighteen studies employed functional neuroimaging techniques such as resting-state and task-based fMRI (emotional, interpersonal exposure/social exclusion, pain, reward, and cognitive processing paradigms). Three studies reported on structural MRI. An association of NSSI behavior and altered emotional processing in cortico-limbic neurocircuitry was commonly reported. Additionally, alterations in potential circuits involving pain, reward, interpersonal, self-processing, and executive function control processes were identified. NSSI has complex and diverse neural underpinnings. Future longitudinal studies are needed to understand its developmental aspects better.
- Pro Re Nata (As Needed) Psychotropic Medication Use in Patients With Borderline Personality Disorder and Subjects With Other Personality Disorders Over 14 Years of Prospective Follow-Up(2014) MARTINHO JR., Eduardo; FITZMAURICE, Garrett M.; FRANKENBURG, Frances R.; ZANARINI, Mary C.The use of pro re nata (PRN; as needed) psychotropic medication in patients with borderline personality disorder (BPD) has not been well characterized. This study had 3 purposes, which are as follows: (1) to describe the prevalence of PRN psychotropic medication use among patients with BPD and comparison subjects with other personality disorders (OPD) over 14 years of prospective follow-up, (2) to examine the rates reported by patients with BPD who ever recovered and never recovered, and (3) to examine the reasons for taking PRN medication reported by these patients. Overall, the prevalence of PRN psychotropic medication use was initially approximately 3 times higher among patients with BPD than comparison subjects with OPD, with a significant one-third decline in the use of PRN medication reported by patients with BPD over time. In analyses restricted to patients with BPD, patients with BPD who never recovered were approximately twice as likely to use PRN medication than patients with BPD who ever recovered over time. In reasons for use, the rates of PRN medication use to decrease agitation for both diagnostic groups declined significantly over time, whereas they remained significantly higher among patients with BPD. Likewise, patients with BPD who never recovered reported higher use of PRN medication to decrease agitation than patients with BPD who ever recovered over time. The results of this study indicate that PRN psychotropic medication is widely used for the treatment of patients with BPD, particularly those who have not achieved a recovery in both the symptomatic and psychosocial realms. They also suggest that patients with BPD use proportionally more PRN medication to decrease agitation than comparison subjects with OPD, with lower proportional use to reduce agitation found among recovered patients with BPD.
bookPart Tratamento dos transtornos de personalidade(2021) BRANãS, Marcelo José Abduch Adas; CROCI, Marcos Signoretti; RIBEIRO, João Cronemberger Sá; JR, Eduardo MartinhobookPart Transtornos do impulso e suas interfaces com transtorno de personalidade borderline e outros transtornos de personalidade(2022) RODRIGUEZ, Ricardo Asensio; GONçALVES, Marcelo Peixoto; BOTTURA, Henrique Moura Leite; TAVARES, Hermano; MARTINHO JUNIOR, EduardobookPart Terapia comportamental dealética(2021) DORNELLES, Vinícius Guimarães; BRANãS, Marcelo José Abduch Adas; CROCI, Marcos Signoretti; JR, Eduardo MartinhobookPart Transtornos de personalidade(2021) TAVARES, Hermano; TORRES, Renata Ferraz; BRAñAS, Marcelo José Abduch Adas; CROCI, Marcos Signoretti; MARTINHO JR., EduardobookPart Inteligência(2021) CROCI, Marcos Signoretti; BRANãS, Marcelo José Abduch Adas; JúNIOR, Eduardo Martinho- BDNF gene polymorphism, cognition and symptom severity in a Brazilian population-based sample of first-episode psychosis subjects(2012) MARTINHO JR., Eduardo; MICHELON, Leandro; AYRES, Adriana M.; SCAZUFCA, Marcia; MENEZES, Paulo R.; SCHAUFELBERGER, Maristela S.; MURRAY, Robin M.; RUSHE, Teresa M.; VALLADA, Homero; BUSATTO FILHO, GeraldoObjective: To investigate the influence of brain-derived neurotrophic factor (BDNF) gene variations on cognitive performance and clinical symptomatology in first-episode psychosis (FEP). Methods: We performed BDNF val66met variant genotyping, cognitive testing (verbal fluency and digit spans) and assessments of symptom severity (as assessed with the PANSS) in a population-based sample of FEP patients (77 with schizophreniform psychosis and 53 with affective psychoses) and 191 neighboring healthy controls. Results: There was no difference in the proportion of Met allele carriers between FEP patients and controls, and no significant influence of BDNF genotype on cognitive test scores in either of the psychosis groups. A decreased severity of negative symptoms was found in FEP subjects that carried a Met allele, and this finding reached significance for the subgroup with affective psychoses (p < 0.01, ANOVA). Conclusions: These results suggest that, in FEP, the BDNF gene Val66Met polymorphism does not exert a pervasive influence on cognitive functioning but may modulate the severity of negative symptoms.